Helicobacter pylori

Review of triple, dual, 7-day, and other treatment strategies

M (Brian) Fennerty, C. S. Melnyk

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Since the identification of Helicobacter pylori in 1983, the pathogen has become the dominant focus of the investigation of peptic ulceration and gastric carcinoma. During the last 7 years, the efficacy of multiple antimicrobial regimens in curing this infection has been examined. More recently, newer treatment approaches-such as dual therapy and 7-day regimens- have shown a high degree of success and have the potential of improving compliance. Vaccines to prevent acquisition of H pylori, and perhaps clear the organism in infected patients, are under development. Still to be determined are the least expensive, most efficacious, and well-tolerated regimen, and optimal length of treatment.

Original languageEnglish (US)
Pages (from-to)682-688
Number of pages7
JournalFormulary
Volume30
Issue number11
StatePublished - 1995

Fingerprint

Helicobacter pylori
Pylorus
Compliance
Digestion
Stomach
Therapeutics
Vaccines
Carcinoma
Infection

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Helicobacter pylori : Review of triple, dual, 7-day, and other treatment strategies. / Fennerty, M (Brian); Melnyk, C. S.

In: Formulary, Vol. 30, No. 11, 1995, p. 682-688.

Research output: Contribution to journalArticle

@article{2e29349b8fb241488cf407d13f74f890,
title = "Helicobacter pylori: Review of triple, dual, 7-day, and other treatment strategies",
abstract = "Since the identification of Helicobacter pylori in 1983, the pathogen has become the dominant focus of the investigation of peptic ulceration and gastric carcinoma. During the last 7 years, the efficacy of multiple antimicrobial regimens in curing this infection has been examined. More recently, newer treatment approaches-such as dual therapy and 7-day regimens- have shown a high degree of success and have the potential of improving compliance. Vaccines to prevent acquisition of H pylori, and perhaps clear the organism in infected patients, are under development. Still to be determined are the least expensive, most efficacious, and well-tolerated regimen, and optimal length of treatment.",
author = "Fennerty, {M (Brian)} and Melnyk, {C. S.}",
year = "1995",
language = "English (US)",
volume = "30",
pages = "682--688",
journal = "Hospital Formulary",
issn = "0098-6909",
publisher = "Advanstar Communications",
number = "11",

}

TY - JOUR

T1 - Helicobacter pylori

T2 - Review of triple, dual, 7-day, and other treatment strategies

AU - Fennerty, M (Brian)

AU - Melnyk, C. S.

PY - 1995

Y1 - 1995

N2 - Since the identification of Helicobacter pylori in 1983, the pathogen has become the dominant focus of the investigation of peptic ulceration and gastric carcinoma. During the last 7 years, the efficacy of multiple antimicrobial regimens in curing this infection has been examined. More recently, newer treatment approaches-such as dual therapy and 7-day regimens- have shown a high degree of success and have the potential of improving compliance. Vaccines to prevent acquisition of H pylori, and perhaps clear the organism in infected patients, are under development. Still to be determined are the least expensive, most efficacious, and well-tolerated regimen, and optimal length of treatment.

AB - Since the identification of Helicobacter pylori in 1983, the pathogen has become the dominant focus of the investigation of peptic ulceration and gastric carcinoma. During the last 7 years, the efficacy of multiple antimicrobial regimens in curing this infection has been examined. More recently, newer treatment approaches-such as dual therapy and 7-day regimens- have shown a high degree of success and have the potential of improving compliance. Vaccines to prevent acquisition of H pylori, and perhaps clear the organism in infected patients, are under development. Still to be determined are the least expensive, most efficacious, and well-tolerated regimen, and optimal length of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0028847476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028847476&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 682

EP - 688

JO - Hospital Formulary

JF - Hospital Formulary

SN - 0098-6909

IS - 11

ER -